expressed in Hodgkin disease

1. Lu W, Andrieu JM. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood. 2000;96:250-258. 2. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART): Swiss HIV cohort study. Lancet. 1998;351:723-724. 3. Levitz SM. Improvement in CD41 cell counts despite persistently detectable HIV load. N Engl J Med. 1998;338:1074-1075. 4. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study: SwissHIV cohort study. Lancet. 1999;353:863-868. 5. Grabar S, Moing VL, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133:401-410. 6. Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS. 1998;12: F123–F129. 7. Bofill M, Borthwick NJ, Simmonds HA. Novel mechanism for the impairment of cell proliferation in HIV-1 infection. Immunol Today. 1999;20:258-261. 8. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999; 5:83-89. 9. McCune JM, Hanley MB, Cesar D, et al. Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest. 2000;105:R1–R8. 10. Fleury S, Rizzardi GP, Chapuis A, et al. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2000;97:5393-5398. 11. Nielsen SD, Afzelius P, Ersboll AK, Nielsen JO, Hansen JE. Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV-infected patients. Clin Exp Immunol. 1998;114:66-72.